miR-16-5p mediates E2-induced cell proliferation and EMT in benign prostate hyperplasia. [PDF]
Kim JE, An L, Xu Y, Park E, Lee HJ.
europepmc +1 more source
Cyclometalated Au(III) Complexes With C*N^N, N^C*N, and C*N Ligands Through C–H Activation
The complexes [Au(QPhPy)Cl][AuCl4], [Au(QPhCF3Py)Cl][AuCl4], [Au(QPhtBuPy)Cl][AuCl4], [Au(QPhPy)Cl]Cl, [Au(QPyPh)Cl2], [Au(QPyPhCF3)Cl2], [Au(QPyPhtBu)Cl2], [Au(bpyAn)Cl][AuCl4], and [Au(phenAn)Cl][AuCl4] (Q = 8‐quinolinyl, Ph = phenyl, An = anthracen‐9‐yl, Py = pyridyl, bpy = 2,2′′‐bipyridyl, phen = 1,10‐phenanthrolinyl) containing N*C^N, N*C, and NN ...
Pascal L. Jurzick +5 more
wiley +1 more source
Dysregulated Cell Signaling Pathways in Prostate Tumoral Plasticity-Checkpoints. [PDF]
Matei E +5 more
europepmc +1 more source
Holmium laser enucleation of the prostate improves the renal insufficiency of benign prostatic hyperplasia with hydronephrosis. [PDF]
Wang DY, Wu JH, Shen ZY, Zhang ZY, Wu D.
europepmc +1 more source
Causal links of 233 metabolic markers to benign prostatic hyperplasia: Mendelian randomization and RNA-sequencing insights. [PDF]
Zhou P, Zhu Z.
europepmc +1 more source
Systemic Oxidative and Nitrosative Stress in Benign Prostatic Hyperplasia. [PDF]
Biesiadecki M +4 more
europepmc +1 more source
Efficacy and safety of Serenoa repens in benign prostatic disorders: a systematic review of recent clinical evidence. [PDF]
Schwartzmann I +9 more
europepmc +1 more source
5 Alpha Reductase Inhibitors (5ARIs) Monotherapy and Combinations: Current Role in Benign Prostatic Hyperplasia (BPH) Management. [PDF]
Roidos C +4 more
europepmc +1 more source
An intelligent wearable device based on electrical impedance tomography for dynamic and accurate monitoring of voiding function in patients with benign prostatic hyperplasia: protocol for a single-centre self-controlled diagnostic consistency study. [PDF]
Liu Z +10 more
europepmc +1 more source

